Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | RXRB | P28702 | 1/20 | 0.58 |
| ▸ | RXRG | P48443 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321719 | 0.88 | POLB (0.55) | MAOBNR4A2MRGPRX4ALOX5 | |
| SCHEMBL1557166 | 0.87 | MAOB (0.60) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL2902027 | 0.86 | RXRA (0.68) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL1557560 | 0.81 | MAOB (0.66) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL2910095 | 0.77 | MAOB (0.69) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL7347439 | 0.77 | MAOB (0.67) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL5383428 | 0.77 | KMT2A (0.63) | MAOBNR4A2MRGPRX4ALOX5 | |
| SCHEMBL1557204 | 0.76 | RXRA (0.65) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL7348486 | 0.76 | MAOB (0.83) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL1557562 | 0.76 | MAOB (0.64) | MAOBMAOARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2101751-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167377-A1 | Novel compounds | F12, C1R, MRGPRX1 | MAOB 1261/4885MAOA 1891/4885RXRA 209/4885 |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | MAOB 1430/4885MAOA 1325/4885RXRA 294/4885 |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | MAOB 1430/4885MAOA 1325/4885RXRA 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.